These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 11925101

  • 21. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
    Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI.
    Oncogene; 1994 Aug; 9(8):2109-23. PubMed ID: 7913542
    [Abstract] [Full Text] [Related]

  • 22. Activation of the EGF receptor by insertional mutations in its juxtamembrane regions.
    Sorokin A.
    Oncogene; 1995 Oct 19; 11(8):1531-40. PubMed ID: 7478577
    [Abstract] [Full Text] [Related]

  • 23. Regulation of EGF receptor expression and function.
    Gill GN.
    Mol Reprod Dev; 1990 Sep 19; 27(1):46-53. PubMed ID: 2271186
    [Abstract] [Full Text] [Related]

  • 24. Downregulation of the early genomic growth factor response in neu oncogene-transformed cells.
    Sistonen L, Koskinen PJ, Lehväslaiho H, Lehtola L, Bravo R, Alitalo K.
    Oncogene; 1990 Jun 19; 5(6):815-21. PubMed ID: 1972791
    [Abstract] [Full Text] [Related]

  • 25. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
    Qian X, Dougall WC, Fei Z, Greene MI.
    Oncogene; 1995 Jan 05; 10(1):211-9. PubMed ID: 7824275
    [Abstract] [Full Text] [Related]

  • 26. Ligand-independent regulation of ErbB4 receptor phosphorylation by activated Ras.
    Tal-Or P, Erlich S, Porat-Shliom N, Goldshmit Y, Ben-Baruch G, Shaharabani E, Kloog Y, Pinkas-Kramarski R.
    J Cell Biochem; 2006 Aug 15; 98(6):1482-94. PubMed ID: 16518842
    [Abstract] [Full Text] [Related]

  • 27. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling.
    Weng MS, Ho CT, Ho YS, Lin JK.
    Toxicol Appl Pharmacol; 2007 Jan 15; 218(2):107-18. PubMed ID: 17182072
    [Abstract] [Full Text] [Related]

  • 28. Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA.
    Li J, Ma C, Huang Y, Luo J, Huang C.
    Oncogene; 2003 Jan 16; 22(2):211-9. PubMed ID: 12527890
    [Abstract] [Full Text] [Related]

  • 29. Ligand depletion negatively controls the mitogenic activity of epidermal growth factor.
    van de Poll ML, van Rotterdam W, Gadellaa MM, Jacobs-Oomen S, van Zoelen EJ.
    Exp Cell Res; 2005 Apr 01; 304(2):630-41. PubMed ID: 15748906
    [Abstract] [Full Text] [Related]

  • 30. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.
    Arteaga CL.
    J Clin Oncol; 2001 Sep 15; 19(18 Suppl):32S-40S. PubMed ID: 11560969
    [Abstract] [Full Text] [Related]

  • 31. Regulation by EGF is maintained in an overexpressed chimeric EGFR/neu receptor tyrosine kinase.
    Lehväslaiho H, Sistonen L, diRenzo F, Partanen J, Comoglio P, Hölttä E, Alitalo K.
    J Cell Biochem; 1990 Mar 15; 42(3):123-33. PubMed ID: 1969420
    [Abstract] [Full Text] [Related]

  • 32. Signal transduction cascade shared by epidermal growth factor and platelet-derived growth factor is a major pathway for oncogenic transformation in NRK cells.
    Masuda A, Kizaka-Kondoh S, Miwatani H, Terada Y, Nojima H, Okayama H.
    New Biol; 1992 May 15; 4(5):489-503. PubMed ID: 1515413
    [Abstract] [Full Text] [Related]

  • 33. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y, Li X, Jiang J, Frank SJ.
    Oncogene; 2006 Dec 07; 25(58):7565-76. PubMed ID: 16785991
    [Abstract] [Full Text] [Related]

  • 34. Activation of Rho is required for ligand-independent oncogenic signaling by a mutant epidermal growth factor receptor.
    Boerner JL, Danielsen A, McManus MJ, Maihle NJ.
    J Biol Chem; 2001 Feb 02; 276(5):3691-5. PubMed ID: 11110781
    [Abstract] [Full Text] [Related]

  • 35. Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells.
    Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P, Alaoui-Jamali MA.
    Oncogene; 2004 Jul 01; 23(30):5252-6. PubMed ID: 15229656
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 37. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G.
    Int J Biochem Cell Biol; 2007 Aug 07; 39(7-8):1416-31. PubMed ID: 17596994
    [Abstract] [Full Text] [Related]

  • 38. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.
    Grana TM, Rusyn EV, Zhou H, Sartor CI, Cox AD.
    Cancer Res; 2002 Jul 15; 62(14):4142-50. PubMed ID: 12124353
    [Abstract] [Full Text] [Related]

  • 39. Ras-independent oncogenic transformation by an EGF-receptor mutant.
    Boerner JL, McManus MJ, Martin GS, Maihle NJ.
    J Cell Sci; 2000 Mar 15; 113 ( Pt 6)():935-42. PubMed ID: 10683142
    [Abstract] [Full Text] [Related]

  • 40. The EGF receptor: structure, regulation and potential role in malignancy.
    Thompson DM, Gill GN.
    Cancer Surv; 1985 Mar 15; 4(4):767-88. PubMed ID: 2824044
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.